Type 1 ifnα

Manufactured by R&D Systems

Sourced in United States

Type I IFNα is a recombinant human interferon alpha protein that is produced in E. coli cells. It can be used for cell culture and research applications.

Automatically generated - may contain errors

Lab products found in correlation

Anti nk1.1 clone pk136, by BioXCell (1 mentions) Silvestrol, by MedChemExpress (1 mentions)

2 protocols using type 1 ifnα

Modulating Lymphoma with Type I IFN

Check if the same lab product or an alternative is used in the 5 most similar protocols

20,000U of Type I IFNα (R&D systems) was administered intraperitoneally to SRα-tTA/tet-O-MYC mice bearing overt lymphoma for 3 days. On day 3, spleens from treated mice were collected, and subjected to flow cytometry for NK and T cell analysis. PBS-treated mice were used as controls. Absolute cell counts were obtained as described in section ‘Calculation of absolute immune cell counts’. For long-term administration of Type I IFNα, the mice were treated every third day with 20,000 U IFNα or PBS intraperitoneally. 100 µg anti-NK1.1 (clone PK136, BioXCell) or IgG2a control (Clone C1.18.4, BioXCell) were administered intraperitoneally every sixth day to deplete NK cells. 2.5 mg anti-IFNAR1 (clone MAR1-6A3, Leinco) or IgG1 control (clone HKSP, Leinco) were administered intraperitoneally to block IFNAR1 in SRα-tTA/tet-O-MYC mice bearing overt lymphoma at the same time as the mice were subjected to MYC inactivation with doxycycline treatment. After 4 days, spleen was collected and subjected to flow cytometry for NK and T cell analysis.

Swaminathan S., Hansen A.S., Heftdal L.D., Dhanasekaran R., Deutzmann A., Fernandez W.D., Liefwalker D.F., Horton C., Mosley A., Liebersbach M., Maecker H.T, & Felsher D.W. (2020). MYC functions as a switch for natural killer cell-mediated immune surveillance of lymphoid malignancies. Nature Communications, 11, 2860.

+ Open protocol

+ Expand

Screening of Rocaglate Derivatives

Cited 1 time

Check if the same lab product or an alternative is used in the 5 most similar protocols

A total of 205 rocaglate derivatives were provided by the Boston University Center for Molecular Discovery (BU-CMD) as racemic mixtures (Roche et al., 2010 (link); Rodrigo et al., 2012 (link); Wang et al., 2016 (link); Zhang et al., 2019a (link), 2019b (link)). In the initial screen we also included 63 rocaglates as enantioenriched samples (see also Supplementary Figure S1). Notably, the BU-CMD collection also contains multiple copies of selected compounds. Top performing compounds identified were all ADRs which are synthesized using an intercepted retro-Nazarov reaction according to a literature procedure (Zhang et al., 2019a (link)). Compounds were dissolved in neat dimethyl sulfoxide (DMSO) to 2 mM concentration and stored at − 80 °C prior to use. Silvestrol was purchased from MedChem Express (Monmouth Junction, NJ, USA) and type I IFN-α was purchased from R&D systems. All compounds were stored and diluted according to manufacturer’s recommendations.

Praditya D.F., Klöhn M., Brüggemann Y., Brown L.E., Porco JA J.r., Zhang W., Kinast V., Kirschning A., Vondran F.W., Todt D, & Steinmann E. (2022). Identification of structurally re-engineered rocaglates as inhibitors against Hepatitis E virus replication. Antiviral research, 204, 105359.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!